Palatin Technologies is a biotechnology business based in the US. Palatin Technologies shares (PTN) are listed on the NYSE MKT and all prices are listed in US Dollars. Its last market close was $0.91 – a decrease of 14.56% over the previous week. Palatin Technologies employs 30 staff and has a trailing 12-month revenue of around $4.5 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.91 |
|---|---|
| 52-week range | $0.68 - $5.65 |
| 50-day moving average | $1.12 |
| 200-day moving average | $1.79 |
| Wall St. target price | $17.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.82 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.93 from 2024-11-19
| 1 week (2024-11-14) | -13.08% |
|---|---|
| 1 month (2024-10-21) | -7.92% |
| 3 months (2024-08-21) | -36.73% |
| 6 months (2024-05-21) | -55.07% |
| 1 year (2023-11-21) | -53.73% |
|---|---|
| 2 years (2022-11-21) | -78.32% |
| 3 years (2021-11-19) | 9.0025 |
| 5 years (2019-11-21) | 20.245 |
| Revenue TTM | $4.5 million |
|---|---|
| Gross profit TTM | $-18,195,369 |
| Return on assets TTM | -131.96% |
| Return on equity TTM | -623.2% |
| Profit margin | 0% |
| Book value | $-0.01 |
| Market Capitalization | $20.9 million |
TTM: trailing 12 months
We're not expecting Palatin Technologies to pay a dividend over the next 12 months.
Palatin Technologies's shares were split on a 1:25 basis on 30 August 2022 . So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Palatin Technologies shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Palatin Technologies shares which in turn could have impacted Palatin Technologies's share price.
Over the last 12 months, Palatin Technologies's shares have ranged in value from as little as $0.68 up to $5.65. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while Palatin Technologies's is 0.94. This would suggest that Palatin Technologies's shares are less volatile than average (for this exchange).
Palatin Technologies, Inc. , a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. Palatin Technologies, Inc.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.